ConductScience.org, home

Paper37627273

Chronic Hepatitis B Infection: New Approaches towards Cure.

Ogunnaike M and 8 others. Biomolecules, 2023. Cited by 25 papers, by iCite.

Cite this record

ConductScience Library. Chronic Hepatitis B Infection: New Approaches towards Cure. Papers, record 37627273. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37627273

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Chronic Hepatitis B Infection: New Approaches towards Cure.
PubMed
Journal
Biomolecules
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
25
iCite
Relative citation ratio, by iCite
2.94
iCite
Revised in PubMed
2023-12-29
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ogunnaike MMojisola
2Das SSrijanee
3Raut SSSamiksha S
4Sultana AAshrafi
5Nayan MUMohammad Ullah
6Ganesan MMurali
7Edagwa BJBenson J
8Osna NANatalia Ahttps://orcid.org/0000-0001-7498-0556
9Poluektova LYLarisa Yhttps://orcid.org/0000-0001-7339-8732

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hepatitis B, ChronicMajor topic
Hepatitis BMajor topic
Liver NeoplasmsMajor topic
Humans
DNA, Viral
Antiviral Agents

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 DK135817NIDDK NIH HHSUnited StatesR01DK135817PubMed and NIHNIH RePORTER
K01 AA026864NIAAA NIH HHSUnited StatesK01AA026864PubMed and NIHNIH RePORTER
R01 AA027189NIAAA NIH HHSUnited StatesR01AA027189PubMed and NIHNIH RePORTER
P50 AA030407NIAAA NIH HHSUnited StatesP50AA030407PubMed and NIHNIH RePORTER
R01 AI163042NIAID NIH HHSUnited StatesR01AI163042PubMed and NIHNIH RePORTER

Download CSV of grants

References158

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119399806Benefits and risks of interferon therapy for hepatitis B.Hepatology2009https://conductscience.org/library/papers/19399806PubMed
230506691Real-world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load.Aliment Pharmacol Ther2019https://conductscience.org/library/papers/30506691PubMed
336686591Tenofovir use is associated with a decreased risk of hepatocellular carcinoma among men with HIV irrespective of coinfection status.JHEP Rep2023https://conductscience.org/library/papers/36686591PubMed
432278307Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing.Mol Ther Nucleic Acids2020https://conductscience.org/library/papers/32278307PubMed
531147612The next generation of CRISPR-Cas technologies and applications.Nat Rev Mol Cell Biol2019https://conductscience.org/library/papers/31147612PubMed
636960800Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men.Hepatology2023https://conductscience.org/library/papers/36960800PubMed
724690881A guide to genome engineering with programmable nucleases.Nat Rev Genet2014https://conductscience.org/library/papers/24690881PubMed
836820558Meta-analysis of the occurrence of hepatocellular carcinoma after the treatment of entecavir and tenofovir for chronic hepatitis B.Medicine (Baltimore)2023https://conductscience.org/library/papers/36820558PubMed
936404234Highly dynamic changes of regional HBV epidemiology over two decades.Dig Liver Dis2023https://conductscience.org/library/papers/36404234PubMed
1034303003Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B.Clin Res Hepatol Gastroenterol2022https://conductscience.org/library/papers/34303003PubMed
1127132172First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B.J Hepatol2016https://conductscience.org/library/papers/27132172PubMed
1233333207Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV.J Hepatol2021https://conductscience.org/library/papers/33333207PubMed
1328647765Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis.Abdom Radiol (NY)2018https://conductscience.org/library/papers/28647765PubMed
1418240869Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.Antivir Ther2007https://conductscience.org/library/papers/18240869PubMed
1535238624Electroporation-Mediated Delivery of Cas9 Ribonucleoproteins Results in High Levels of Gene Editing in Primary Hepatocytes.CRISPR J2022https://conductscience.org/library/papers/35238624PubMed
1633395488Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study.Clin Infect Dis2021https://conductscience.org/library/papers/33395488PubMed
1733341047Inappropriate cessation of nucleos(t)ide analog associated with reduced liver transplant-free survival in patients with HBV-related acute on chronic liver failure.Biomed Pharmacother2021https://conductscience.org/library/papers/33341047PubMed
1829940226Design and in vivo evaluation of entecavir-3-palmitate microcrystals for subcutaneous sustained delivery.Eur J Pharm Biopharm2018https://conductscience.org/library/papers/29940226PubMed
1925402233Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.AIDS Res Hum Retroviruses2015https://conductscience.org/library/papers/25402233PubMed
2034531390Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles.Nat Commun2021https://conductscience.org/library/papers/34531390PubMed

See all 158 referencesDownload CSV of references

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.

PMIDTitleJournalYearIn PapersSource
42503913[Clinical significance and occurrence mechanism of hepatitis B virus DNA integration].Zhonghua Gan Zang Bing Za Zhi2026https://conductscience.org/library/papers/42503913PubMed
42467124AURKA regulates HBV-induced hepatic stellate cell inflammation and liver fibrosis by modulating K48-linked ubiquitination and proteasomal degradation of TLR3.J Bioenerg Biomembr2026https://conductscience.org/library/papers/42467124PubMed
42243721Antiviral therapy and hidden predictors of postoperative outcomes in hepatocellular carcinoma.BMC Cancer2026https://conductscience.org/library/papers/42243721PubMed
41830105HBV RNA Predicts the Risk of Off-Treatment Relapse in Chronic Hepatitis B Patients With NAs Therapy: A Systematic Review and Meta-Analysis.J Viral Hepat2026https://conductscience.org/library/papers/41830105PubMed
41676540Adenine Base Editing Potently Suppresses Hepatitis B Surface Antigen Expression and Inhibits Hepatitis D Virus Release.bioRxiv2026https://conductscience.org/library/papers/41676540PubMed
41341015Knowledge, Attitudes, and Practices Regarding Hepatitis B and Liver Cancer Among Liver Cancer Patients and Their Families in China.Cancer Manag Res2025https://conductscience.org/library/papers/41341015PubMed
40872772The Evolution of Cell Culture Systems to Study Hepatitis B Virus Pathogenesis and Antiviral Susceptibility.Viruses2025https://conductscience.org/library/papers/40872772PubMed
40749058A scalable ultra-long-acting tenofovir phosphonate prodrug sustains HBV suppression.Sci Adv2025https://conductscience.org/library/papers/40749058PubMed
40687725An in-depth investigation of NAs-induced osteoporosis adverse events: a real-world, network toxicology and molecular docking analysis.Front Med (Lausanne)2025https://conductscience.org/library/papers/40687725PubMed
40575574Construction and validation of a nomogram prediction model for antiviral efficacy based on clinical characteristics and intestinal microflora distribution in patients with chronic hepatitis B.Front Med (Lausanne)2025https://conductscience.org/library/papers/40575574PubMed
40143195Potential Benefits of In Silico Methods: A Promising Alternative in Natural Compound's Drug Discovery and Repurposing for HBV Therapy.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/40143195PubMed
40092015Chronic Hepatitis B Virus Persistence: Mechanisms and Insights.Cureus2025https://conductscience.org/library/papers/40092015PubMed
39980283Clinical and In vitro Data Shed New Light on the Therapeutic Advantages of Black Seeds (Nigella sativa) for the Treatment of Hepatitis C and Hepatitis B Viral Infections.Infect Disord Drug Targets2025https://conductscience.org/library/papers/39980283PubMed
39860969Surveillance Following Hepatitis B Surface Antigen Loss: An Issue Requiring Attention.Pathogens2024https://conductscience.org/library/papers/39860969PubMed
39804828Pharmacophore modeling and QSAR analysis of anti-HBV flavonols.PLoS One2025https://conductscience.org/library/papers/39804828PubMed
39572840Hepatitis B and D virus entry.Nat Rev Microbiol2025https://conductscience.org/library/papers/39572840PubMed
39459899Applications of CRISPR/Cas as a Toolbox for Hepatitis B Virus Detection and Therapeutics.Viruses2024https://conductscience.org/library/papers/39459899PubMed
38858185[A new concept from a global perspective for expanding the treatment of chronic hepatitis B].Zhonghua Gan Zang Bing Za Zhi2024https://conductscience.org/library/papers/38858185PubMed
38668246Prospects for Controlling Hepatitis B Globally.Pathogens2024https://conductscience.org/library/papers/38668246PubMed
38612717Insights into the Management of Chronic Hepatitis in Children-From Oxidative Stress to Antioxidant Therapy.Int J Mol Sci2024https://conductscience.org/library/papers/38612717PubMed

See all 23 cited byDownload CSV of cited by

Genes14

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37627273

GET https://conductscience.org/api/papers/v1/37627273/references?page=2